Figure 2.

Trametinib with pazopanib causes regression of established DTC xenograft tumors. (A) 8505C or (B) CAL62 cells were implanted in the flanks of athymic nu/nu mice and allowed to grow to 0.1 to 0.2 cm³. Groups of 11 mice were randomized to receive trametinib 1 mg/kg, pazopanib 100 mg/kg, the combination or vehicle alone, by daily oral gavage. Dashed lines in A and B indicate 50% regression compared to the starting volume. Kaplan-Meier analyses for tumor progression are shown for (C) 8505C and (D) CAL62 tumors, ^*p=0.03 vs. vehicle, ^**p<0.0001 vs. vehicle. DTC, differentiated thyroid cancer.